治療薬の世界市場分析:製品別(消耗品、機器、データ管理サービス)、技術別(イムノアッセイ、プロテオーム技術)、薬品別(抗てんかん剤、抗生物質、免疫抑制剤、抗不整脈剤)、エンドユーザー別(病院研究室、私設研究室)、セグメント予測...市場調査レポートについてご紹介

【英文タイトル】Therapeutic Drug Monitoring Market Analysis By Product (Consumables, Equipment, Data Management Services), By Technology (Immunoassays, Proteomic Technologies) By Drug Class (Anti-epileptic s, Antibiotics, Immunosuppressants, Anti-arrhythmics) By End-use (Hospital Labs, Private Labs), and Segment Forecasts To 2024

▼当市場調査レポートの詳細内容確認、お問い合わせ及びご購入申込は下記ページでお願いします。▼マーケットレポート

【レポートの概要(一部)】

Table of Content

Chapter 1.Methodology And Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
1.3. List of Data Sources
Chapter 2. Executive Summary
2.1. Therapeutic drug monitoring market – Industry Snapshot and Key Buying Criteria, 2013 – 2024
Chapter 3. Therapeutic Drug Monitoring Market, Industry Outlook
3.1. Market segmentation
3.2. Market size and growth prospects
3.3. Therapeutic drug monitoring market: Market dynamics
3.3.1. Market driver analysis
3.3.2. Market restraint analysis
3.4. Key opportunities prioritized
3.5. Industry Analysis – Porter’s
3.6. Therapeutic drug monitoring market PESTEL analysis, 2015
Chapter 4. Therapeutic Drug Monitoring Market, Product Outlook
4.1. Therapeutic drug monitoring market share by product, 2015 & 2024
4.2. Consumables
4.2.1. Consumables market estimates and forecasts, 2013 – 2024 (USD Million)
4.3. Equipment
4.3.1. Equipment market estimates and forecasts, 2013 – 2024 (USD Million)
4.4. Others
4.4.1. Others market estimates and forecasts, 2013 – 2024 (USD Million)
Chapter 5. Therapeutic Drug Monitoring Market, Technology Outlook
5.1. Therapeutic drug monitoring market share by technology, 2015 & 2024
5.2. Immunoassays
5.2.1. Immunoassays market estimates and forecasts, 2013 – 2024 (USD Million)
5.3. Proteomic technologies
5.3.1. Proteomic technologies market estimates and forecasts, 2013 – 2024 (USD Million)
5.4. Others
5.4.1. Others market estimates and forecasts, 2013 – 2024 (USD Million)
Chapter 6. Therapeutic Drug Monitoring Market, Drug Class Outlook
6.1. Therapeutic drug monitoring market share by drug class, 2015 & 2024
6.2. Anti – epileptics
6.2.1. Anti – epileptic market estimates and forecasts, 2013 – 2024 (USD Million)
6.3. Antibiotics
6.3.1. Antibiotics market estimates and forecasts, 2013 – 2024 (USD Million)
6.4. Immunosuppressants
6.4.1. Immunosuppressants market estimates and forecasts, 2013 – 2024 (USD Million)
6.5. Psychoactive drugs
6.5.1. Psychoactive drugs market estimates and forecasts, 2013 – 2024 (USD Million)
6.6. Anti-arrhythmic drugs
6.6.1. Anti-arrhythmic drugs market estimates and forecasts, 2013 – 2024 (USD Million)
6.7. Others
6.7.1. Others drug market estimates and forecasts, 2013 – 2024 (USD Million)
Chapter 7. Therapeutic Drug Monitoring Market, End – use Outlook
7.1. Therapeutic drug monitoring market share by end – use, 2015 & 2024
7.2. Hospital labs
7.2.1. Hospital labs market estimates and forecasts, 2013 – 2024 (USD Million)
7.3. Private labs
7.3.1. Private labs market estimates and forecasts, 2013 – 2024 (USD Million)
7.4. Others
7.4.1. Others market estimates and forecasts, 2013 – 2024 (USD Million)
Chapter 8. Drug Monitoring Market Regional Outlook
8.1. Therapeutic drug monitoring market share by region, 2015 & 2024
8.2. North America
8.2.1. North America market estimates and forecasts, by product, 2013 – 2024 (USD Million)
8.2.1.1. U.S. market estimates and forecasts
8.2.1.2. Canada market estimates and forecasts
8.2.2. North America market estimates and forecasts, by technology type, 2013 – 2024 (USD Million)
8.2.2.1. U.S. market estimates and forecasts
8.2.2.2. Canada market estimates and forecasts
8.2.3. North America market estimates and forecasts, by drug class, 2013 – 2024 (USD Million)
8.2.3.1. U.S. market estimates and forecasts
8.2.3.2. Canada market estimates and forecasts
8.2.4. North America market estimates and forecasts, by end – use type, 2013 – 2024 (USD Million)
8.2.4.1. U.S. market estimates and forecasts
8.2.4.2. Canada market estimates and forecasts
8.3. Europe
8.3.1. Europe market estimates and forecasts, by product , 2013 – 2024 (USD Million)
8.3.1.1. UK market estimates and forecasts
8.3.1.2. Germany market estimates and forecasts
8.3.2. Europe market estimates and forecasts, by technology, 2013 – 2024 (USD Million)
8.3.2.1. UK market estimates and forecasts
8.3.2.2. Germany market estimates and forecasts
8.3.3. Europe market estimates and forecasts, by drug class, 2013 – 2024 (USD Million)
8.3.3.1. UK market estimates and forecasts
8.3.3.2. Germany market estimates and forecasts
8.3.4. Europe market estimates and forecasts, by end – use, 2013 – 2024 (USD Million)
8.3.4.1. UK market estimates and forecasts
8.3.4.2. Germany market estimates and forecasts
8.4. Asia Pacific
8.4.1. Asia Pacific market estimates and forecasts, by product, 2013 – 2024 (USD Million)
8.4.1.1. Japan market estimates and forecasts
8.4.1.2. China market estimates and forecasts
8.4.2. Asia Pacific market estimates and forecasts, by technology, 2013 – 2024 (USD Million)
8.4.2.1. Japan market estimates and forecasts
8.4.2.2. China market estimates and forecasts
8.4.3. Asia Pacific market estimates and forecasts, by drug class, 2013 – 2024 (USD Million)
8.4.3.1. Japan market estimates and forecasts
8.4.3.2. China market estimates and forecasts
8.4.4. Asia Pacific market estimates and forecasts, by end – use , 2013 – 2024 (USD Million)
8.4.4.1. Japan market estimates and forecasts
8.4.4.2. China market estimates and forecasts
8.5. Latin America
8.5.1. Latin America market estimates and forecasts, by product, 2013 – 2024 (USD Million)
8.5.1.1. Brazil market estimates and forecasts
8.5.2. Latin America market estimates and forecasts, by technology, 2013 – 2024 (USD Million)
8.5.2.1. Brazil market estimates and forecasts
8.5.3. Latin America market estimates and forecasts, by drug class, 2013 – 2024 (USD Million)
8.5.3.1. Brazil market estimates and forecasts
8.5.4. Latin America market estimates and forecasts, by end – use, 2013 – 2024 (USD Million)
8.5.4.1. Brazil market estimates and forecasts
8.6. MEA
8.6.1. MEA market estimates and forecasts, by product , 2013 – 2024 (USD Million)
8.6.1.1. South Africa market estimates and forecast
8.6.2. MEA market estimates and forecasts, by technology, 2013 – 2024 (USD Million)
8.6.2.1. South Africa market estimates and forecast
8.6.3. MEA market estimates and forecasts, by drug class, 2013 – 2024 (USD Million)
8.6.3.1. South Africa market estimates and forecast
8.6.4. MEA market estimates and forecasts, by end – use, 2013 – 2024 (USD Million)
8.6.4.1. South Africa market estimates and forecast
Chapter 9. Competitive Landscape
9.1. Roche Diagnostics
9.1.1. Company Overview
9.1.2. Financial Performance
9.1.3. Product Benchmarking
9.1.4. Strategic Initiatives
9.2. biomérieux, Inc.
9.2.1. Company Overview
9.2.2. Financial Performance
9.2.3. Product Benchmarking
9.2.4. Strategic Initiatives
9.3. Abbott Laboratories, Inc.
9.3.1. Company Overview
9.3.2. Financial Performance
9.3.3. Product Benchmarking
9.3.4. Strategic Initiatives
9.4. Danaher Corporation
9.4.1. Company Overview
9.4.2. Financial Performance
9.4.3. Product Benchmarking
9.4.4. Strategic Initiatives
9.5. Alere, Inc.
9.5.1. Company Overview
9.5.2. Financial Performance
9.5.3. Product Benchmarking
9.5.4. Strategic Initiatives
9.6. Agilent Technologies, Inc.
9.6.1. Company Overview
9.6.2. Financial Performance
9.6.3. Product Benchmarking
9.6.4. Strategic Initiatives
9.7. Thermo Fisher Scientific, Inc.
9.7.1. Company Overview
9.7.2. Financial Performance
9.7.3. Product Benchmarking
9.7.4. Strategic Initiatives
9.8. Siemens Healthcare GmbH
9.8.1. Company Overview
9.8.2. Financial Performance
9.8.3. Product Benchmarking
9.8.4. Strategic Initiatives
9.9. Bio-Rad Laboratories, Inc.
9.9.1. Company Overview
9.9.2. Financial Performance
9.9.3. Product Benchmarking
9.9.4. Strategic Initiatives


【レポート販売概要】

■ タイトル:治療薬の世界市場分析:製品別(消耗品、機器、データ管理サービス)、技術別(イムノアッセイ、プロテオーム技術)、薬品別(抗てんかん剤、抗生物質、免疫抑制剤、抗不整脈剤)、エンドユーザー別(病院研究室、私設研究室)、セグメント予測
■ 英文:Therapeutic Drug Monitoring Market Analysis By Product (Consumables, Equipment, Data Management Services), By Technology (Immunoassays, Proteomic Technologies) By Drug Class (Anti-epileptic s, Antibiotics, Immunosuppressants, Anti-arrhythmics) By End-use (Hospital Labs, Private Labs), and Segment Forecasts To 2024
■ 発行日:2016年8月18日
■ 調査会社:Grand View Research
■ 商品コード:GVIEW707842
■ 調査対象地域:グローバル
※当サイトは世界の市場調査レポート紹介サイトです。市場規模、市場動向、市場予測など、多様な分析データを含むグローバル調査レポートをご案内致します。日本国内を含むアジア太平洋、中国、ヨーロッパ、アメリカ、北米、中南米、中東、アフリカ地域などにおける、製品、サービス、技術、企業(メーカー、ベンダー)、市場シェア、市場環境など多様な項目に対応致します。当サイトでご紹介するレポートは「市場調査レポート販売サイトのMarketReport.jp」でお問い合わせ及びご購入可能です。